Related Experiment Video
Updated: Feb 16, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
A critical appraisal of the updated 2014 Nice Pulmonary Hypertension Classification System
Edmund M T Lau1, Marc Humbert2
1AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; INSERM UMR_S999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France; Sydney Medical School, University of Sydney, Camperdown, Australia.
Abstract:
In 2013, the Fifth World Symposium on Pulmonary Hypertension (PH) was held in Nice, France. This meeting has been held every 5 years since the Second World Symposium in 1998, when the modern-day classification system of PH was initially conceived. PH is a pathophysiologic state of the pulmonary circulation characterized by an increased mean pulmonary artery pressure ≥ 25 mm Hg at rest, and can be the consequence of a variety of distinct disease entities. The rationale of a classification system for PH was to group together disease entities that share similar pathomechanisms, clinical presentation, and therapeutic approaches. Refinements of the classification system have been made at each subsequent World Symposium, reflecting the ongoing research and new knowledge acquired in the science of PH. We provide an update of the recent changes made to the PH classification system from the Nice meeting.
More Related Videos
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Lazarus's Cognitive Appraisal Theory
Primary Appraisal:...